molecules of the month


oral Mtb 23S bacterial ribosome inhibitor

potent in vitro + in vivo activity against Mycobacterium tuberculosis

opt. of sequanamycin macrolides

Cell, February 23, 2023

Sanofi, FR +CH

SEQ9, oral bacterial ribosome inhibitor, potent in vitro + in vivo activity against Mycobacterium tuberculosis, SANOFI, FR + CH
4 mins read

Overview. A common route of resistance to tuberculosis involves Mtb erm37 expression, which expresses an RNA methyltransferase that methylates the A2058 position of the 23S ribosome RNA, hindering macrolide antibiotic binding. The sequanamycins (SEQs) are a class of molecules that overcomes this resistance mechanism, primarily attributed to the change from a dimethylamine to a carbonyl/oxime, which appears to compensate for the change in a key water molecule lacking in the mutant. Key to improving oral bioavailability and overall PK were the increase in acid and liver stability through use of an uncommon 1,4-oxazepane. The oral efficacy of the molecule is remarkable given its beyond the rule of 5 (bRo5) properties. SEQs overcome a well-known RNA-based resistance mechanism in Mycobacterium tuberculosis…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: